QPS tapped for Acticor Biotech FIH study

By Melissa Fassbender contact

- Last updated on GMT

QPS tapped for Acticor Biotech FIH study

Related tags: Contract research organization

Acticor Biotech has contracted QPS to manage a Phase I study of the company’s humanized Antibody Fragment, ACT017.

Acticor is developing ACT017, a humanized Antibody Fragment (Fab) directed against platelet glycoprotein VI (GPVI).

According to the company, the antithrombotic efficacy of ACT017 and safety of inhibition of GPVI have been established ex vivo and in vivo.

QPS will conduct the first-in-human study​ at its facilities in Groningen, the Netherlands with the goal of assessing safety and tolerance in addition to parameters of haemostasis and coagulation.

The contract research organization (CRO) will also determine pharmacokinetic and pharmacodynamics parameters.

Submission is planned for September 2017 and the first volunteer cohort is planned for October 2017.

The clinical study will enroll 48 subjects in six escalating dose level cohorts, with each cohort consisting of 8 subjects.

(Feature image: iStock/shironosov)

Related topics: Clinical Development, Phase I-II

Related news

Show more

Related products

show more

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Related suppliers

Follow us

Products

View more

Webinars